Brazhnik Kristina, Sokolova Zinaida, Baryshnikova Maria, Bilan Regina, Efimov Anton, Nabiev Igor, Sukhanova Alyona
Laboratory of Nano-Bioengineering, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow, Russian Federation.
Laboratory of Nano-Bioengineering, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow, Russian Federation; Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation.
Nanomedicine. 2015 Jul;11(5):1065-75. doi: 10.1016/j.nano.2015.03.003. Epub 2015 Mar 21.
An immunodiagnostic lab-on-a-bead suspension microarray based on microbeads encoded with quantum dots (QDs) has been developed and preclinically validated for multiplexed quantitative detection of prostate cancer markers in human serum samples. The sensitivity and specificity of the microarray are similar to those of "gold-standard" single-analyte ELISA. Moreover, the array has an improved immunoassay capacity, ensures quantitative detection of multiple cancer biomarkers and may be operational in a considerably wider dynamic range of concentrations. The array is characterized by reduced time and cost of analysis and is compatible with classical flow cytometers. Proof-of-concept preclinical tests ensured simultaneous quantitative determination of free and total prostate-specific antigens in human serum, with clear discrimination between the control and clinical samples. The proposed approach is flexible and paves the way to development of a wide variety of immunodiagnostic assays for multiplexed early diagnosis of various diseases.
Early diagnosis of cancer can result in better prognosis for patients. Thus, the use of specific tumor markers is widely employed in clinical practice. Traditional screening methods only employ single markers. The authors here developed a microarray system based on microbeads encoded with quantum dots (QDs), which can be used for multiplexed quantitative detection. The validated results on patient samples should lead to the development of a wider variety of assays for other diseases.
一种基于量子点（QD）编码微珠的免疫诊断微珠悬浮芯片已被开发出来，并在临床前得到验证，可用于对人血清样本中的前列腺癌标志物进行多重定量检测。该芯片的灵敏度和特异性与“金标准”单分析物酶联免疫吸附测定（ELISA）相似。此外，该芯片具有更高的免疫测定能力，可确保对多种癌症生物标志物进行定量检测，并且可能在相当宽的浓度动态范围内有效运行。该芯片的特点是分析时间和成本降低，并且与传统流式细胞仪兼容。临床前概念验证测试确保了对人血清中游离和总前列腺特异性抗原的同时定量测定，能够清晰地区分对照样本和临床样本。所提出的方法具有灵活性，为开发用于多种疾病多重早期诊断的各种免疫诊断测定方法铺平了道路。
癌症的早期诊断可以为患者带来更好的预后。因此，特定肿瘤标志物的使用在临床实践中被广泛采用。传统的筛查方法只使用单一标志物。本文作者开发了一种基于量子点（QD）编码微珠的芯片系统，可用于多重定量检测。在患者样本上的验证结果应该会促使开发出针对其他疾病的更多种检测方法。
